7/103 sources · 2 publishersUpdated Oct 21, 12:46 UTC
Voyager Therapeutics appoints Robin Swartz as president and future CEO
Voyager Therapeutics announced that Robin Swartz will become president on October 20, 2026. The company said she will take over as chief executive officer in the first quarter of 2027, once safety data from the VY1706 trial are received. Current CEO Alfred W. Sandrock, Jr. will stay on the board after the transition.
Why it matters
The leadership change could affect Voyager's strategic direction and execution of its gene‑therapy pipeline. Investors will watch the upcoming trial data, as the CEO succession is tied to that outcome.
Key facts
- 1Robin Swartz was appointed president effective October 20, 2026. tradingview.com
- 2She is slated to become CEO in Q1 2027, contingent on initial safety data from the VY1706 clinical trial. tradingview.com
- 3Alfred W. Sandrock, Jr. will remain a board member after stepping down as CEO. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.